vs
ITRON, INC.（ITRI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ITRON, INC.的1.3倍（$772.1M vs $587.0M），Revvity净利率更高（12.7% vs 9.1%，领先3.6%），Revvity同比增速更快（5.9% vs -3.3%），Revvity自由现金流更多（$161.8M vs $79.0M），过去两年Revvity的营收复合增速更高（9.0% vs -1.8%）
Itron, Inc.是美国一家专注于能源与水资源管理的技术企业，总部位于华盛顿州自由湖。公司提供电、气、水及热能计量设备、控制技术、通信系统、配套软件，同时还提供托管运营及咨询服务，可对能源和水资源的消耗情况进行计量与深度分析，助力相关领域的资源高效管理。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ITRI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$587.0M
营收增速更快
RVTY
高出9.2%
-3.3%
净利率更高
RVTY
高出3.6%
9.1%
自由现金流更多
RVTY
多$82.8M
$79.0M
两年增速更快
RVTY
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $587.0M | $772.1M |
| 净利润 | $53.6M | $98.4M |
| 毛利率 | 40.3% | — |
| 营业利润率 | 11.5% | 14.5% |
| 净利率 | 9.1% | 12.7% |
| 营收同比 | -3.3% | 5.9% |
| 净利润同比 | -18.0% | 3.9% |
| 每股收益（稀释后） | $1.18 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITRIRVTY
| Q1 26 | $587.0M | — | ||
| Q4 25 | $571.7M | $772.1M | ||
| Q3 25 | $581.6M | $698.9M | ||
| Q2 25 | $606.8M | $720.3M | ||
| Q1 25 | $607.2M | $664.8M | ||
| Q4 24 | $612.9M | $729.4M | ||
| Q3 24 | $615.5M | $684.0M | ||
| Q2 24 | $609.1M | $691.7M |
净利润ITRIRVTY
| Q1 26 | $53.6M | — | ||
| Q4 25 | $101.6M | $98.4M | ||
| Q3 25 | $65.6M | $46.7M | ||
| Q2 25 | $68.3M | $53.9M | ||
| Q1 25 | $65.5M | $42.2M | ||
| Q4 24 | $58.1M | $94.6M | ||
| Q3 24 | $78.0M | $94.4M | ||
| Q2 24 | $51.3M | $55.4M |
毛利率ITRIRVTY
| Q1 26 | 40.3% | — | ||
| Q4 25 | 40.5% | — | ||
| Q3 25 | 37.7% | 53.6% | ||
| Q2 25 | 36.9% | 54.5% | ||
| Q1 25 | 35.8% | 56.5% | ||
| Q4 24 | 34.9% | — | ||
| Q3 24 | 34.1% | 56.3% | ||
| Q2 24 | 34.6% | 55.7% |
营业利润率ITRIRVTY
| Q1 26 | 11.5% | — | ||
| Q4 25 | 13.8% | 14.5% | ||
| Q3 25 | 14.1% | 11.7% | ||
| Q2 25 | 12.6% | 12.6% | ||
| Q1 25 | 12.6% | 10.9% | ||
| Q4 24 | 10.2% | 16.3% | ||
| Q3 24 | 12.0% | 14.3% | ||
| Q2 24 | 10.6% | 12.4% |
净利率ITRIRVTY
| Q1 26 | 9.1% | — | ||
| Q4 25 | 17.8% | 12.7% | ||
| Q3 25 | 11.3% | 6.7% | ||
| Q2 25 | 11.3% | 7.5% | ||
| Q1 25 | 10.8% | 6.4% | ||
| Q4 24 | 9.5% | 13.0% | ||
| Q3 24 | 12.7% | 13.8% | ||
| Q2 24 | 8.4% | 8.0% |
每股收益（稀释后）ITRIRVTY
| Q1 26 | $1.18 | — | ||
| Q4 25 | $2.20 | $0.86 | ||
| Q3 25 | $1.41 | $0.40 | ||
| Q2 25 | $1.47 | $0.46 | ||
| Q1 25 | $1.42 | $0.35 | ||
| Q4 24 | $1.26 | $0.77 | ||
| Q3 24 | $1.70 | $0.77 | ||
| Q2 24 | $1.10 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $712.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $4.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ITRIRVTY
| Q1 26 | $712.9M | — | ||
| Q4 25 | $1.0B | $919.9M | ||
| Q3 25 | $1.3B | $931.4M | ||
| Q2 25 | $1.2B | $991.8M | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $982.5M | $1.2B | ||
| Q2 24 | $920.6M | $2.0B |
总债务ITRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
股东权益ITRIRVTY
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B |
总资产ITRIRVTY
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.6B | $12.4B | ||
| Q1 25 | $3.5B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B |
负债/权益比ITRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 1.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $85.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $79.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.5% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $394.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ITRIRVTY
| Q1 26 | $85.5M | — | ||
| Q4 25 | $119.3M | $182.0M | ||
| Q3 25 | $117.8M | $138.5M | ||
| Q2 25 | $96.7M | $134.3M | ||
| Q1 25 | $72.1M | $128.2M | ||
| Q4 24 | $79.8M | $174.2M | ||
| Q3 24 | $65.3M | $147.9M | ||
| Q2 24 | $51.7M | $158.6M |
自由现金流ITRIRVTY
| Q1 26 | $79.0M | — | ||
| Q4 25 | $111.5M | $161.8M | ||
| Q3 25 | $113.4M | $120.0M | ||
| Q2 25 | $90.7M | $115.5M | ||
| Q1 25 | $67.5M | $112.2M | ||
| Q4 24 | $70.2M | $149.8M | ||
| Q3 24 | $58.7M | $125.6M | ||
| Q2 24 | $44.6M | $136.6M |
自由现金流率ITRIRVTY
| Q1 26 | 13.5% | — | ||
| Q4 25 | 19.5% | 21.0% | ||
| Q3 25 | 19.5% | 17.2% | ||
| Q2 25 | 14.9% | 16.0% | ||
| Q1 25 | 11.1% | 16.9% | ||
| Q4 24 | 11.4% | 20.5% | ||
| Q3 24 | 9.5% | 18.4% | ||
| Q2 24 | 7.3% | 19.7% |
资本支出强度ITRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 1.2% | 3.2% |
现金转化率ITRIRVTY
| Q1 26 | 1.60× | — | ||
| Q4 25 | 1.17× | 1.85× | ||
| Q3 25 | 1.80× | 2.97× | ||
| Q2 25 | 1.41× | 2.49× | ||
| Q1 25 | 1.10× | 3.03× | ||
| Q4 24 | 1.37× | 1.84× | ||
| Q3 24 | 0.84× | 1.57× | ||
| Q2 24 | 1.01× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ITRI
| Product revenues | $477.8M | 81% |
| Service revenues | $109.2M | 19% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
